For help on how to get the results you want, see our search tips.
274 results
Medicine type
Generic Remove Generic filter
Orphan medicine Remove Orphan medicine filter
Accelerated assessment Remove Accelerated assessment filter
Medicine
Summaries of opinion Remove Summaries of opinion filter
Orphan designations Remove Orphan designations filter
Categories
Human Remove Human filter
-
List item
Orphan designation: (1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt (eliglustat) for: Treatment of Gaucher disease
Date of designation: 04/12/2007, Positive, Last updated: 18/07/2023 -
List item
Orphan designation: Humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s (sutimlimab) for: Treatment of autoimmune haemolytic anaemia
Date of designation: 17/02/2016, Positive, Last updated: 18/07/2023 -
List item
Orphan designation: Cyclic pyranopterin monophosphate (fosdenopterin) for: Treatment of molybdenum-cofactor deficiency type A
Date of designation: 20/09/2010, Positive, Last updated: 17/07/2023 -
List item
Orphan designation: Cedazuridine, decitabine for: Treatment of acute myeloid leukaemia
Date of designation: 10/12/2021, Withdrawn, Last updated: 06/07/2023 -
List item
Orphan designation: tasimelteon for: Treatment of non-24-hour sleep-wake disorders in blind people with no light perception
Date of designation: 23/02/2011, Positive, Last updated: 30/06/2023 -
List item
Orphan designation: Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene for: Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency
Date of designation: 26/08/2005, Positive, Last updated: 27/06/2023 -
List item
Orphan designation: Cannabidiol for: Treatment of tuberous sclerosis
Date of designation: 17/01/2018, Positive, Last updated: 15/06/2023 -
List item
Orphan designation: Cannabidiol for: Treatment of Lennox-Gastaut syndrome
Date of designation: 20/03/2017, Positive, Last updated: 14/06/2023 -
List item
Orphan designation: Cannabidiol for: Treatment of Dravet syndrome
Date of designation: 15/10/2014, Positive, Last updated: 14/06/2023 -
List item
Orphan designation: Sirolimus for: Treatment of tuberous sclerosis
Date of designation: 23/08/2017, Positive, Last updated: 09/06/2023 -
List item
Orphan designation: Ivosidenib for: Treatment of biliary tract cancer
Date of designation: 21/03/2018, Positive, Last updated: 12/05/2023 -
List item
Orphan designation: Ivosidenib for: Treatment of acute myeloid leukaemia
Date of designation: 12/12/2016, Positive, Last updated: 12/05/2023 -
List item
Orphan designation: 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor) for: Treatment of sickle cell disease
Date of designation: 18/11/2016, Positive, Last updated: 04/05/2023 -
List item
Orphan designation: Gallium (68Ga)-edotreotide for: Diagnosis of gastro-entero-pancreatic neuroendocrine tumours
Date of designation: 19/03/2015, Positive, Last updated: 03/05/2023 -
List item
Orphan designation: Lutetium (177Lu)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide (lutetium (177Lu) oxodotreotide) for: Treatment of gastro-entero-pancreatic neuroendocrine tumours
Date of designation: 31/01/2008, Positive, Last updated: 03/05/2023 -
List item
Orphan designation: Fenfluramine hydrochloride for: Treatment of Lennox-Gastaut syndrome
Date of designation: 27/02/2017, Positive, Last updated: 25/04/2023 -
List item
Orphan designation: Fenfluramine hydrochloride for: Treatment of Dravet syndrome
Date of designation: 18/12/2013, Positive, Last updated: 25/04/2023 -
List item
Orphan designation: arimoclomol citrate for: Treatment of Niemann-Pick's disease, type C
Date of designation: 19/11/2014, Positive, Last updated: 11/04/2023 -
List item
Orphan designation: Recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept) for: Treatment of beta thalassaemia intermedia and major
Date of designation: 29/07/2014, Positive, Last updated: 21/03/2023 -
List item
Orphan designation: Panobinostat for: Treatment of multiple myeloma
Date of designation: 08/11/2012, Positive, Last updated: 13/03/2023 -
List item
Orphan designation: Treprostinil sodium for: Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Date of designation: 14/04/2004, Positive, Last updated: 13/02/2023 -
List item
Orphan designation: Phosphorothioate oligonucleotide targeted to apolipoprotein C-III (volanesorsen) for: Treatment of familial chylomicronaemia syndrome
Date of designation: 19/02/2014, Positive, Last updated: 02/02/2023 -
List item
Orphan designation: Allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes (Tabelecleucel) for: Treatment of post-transplantation lymphoproliferative disorders
Date of designation: 21/03/2016, Positive, Last updated: 30/01/2023 -
List item
Orphan designation: Bardoxolone methyl for: Treatment of Alport syndrome
Date of designation: 25/05/2018, Positive, Last updated: 30/01/2023 -
List item
Orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor (axicabtagene ciloleucel) for: Treatment of diffuse large B-cell lymphoma
Date of designation: 16/12/2014, Positive, Last updated: 16/12/2022